Role for osteoprotegerin in rheumatoid inflammation

Joint Bone Spine

Volumn 71, Issue 1, 2004, Pages 9-13

  Saidenberg Kermanac'h, Nathalie ^a,c   Cohen Solal, Martine ^b   Bessis, Natacha ^a   De Vernejoul, Marie Christine ^b   Boissier, Marie Christophe ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b CENTRE VIGGO PETERSEN   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Inflammation; Osteolysis; Osteoprotegerin

Indexed keywords

HORMONE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

BINDING AFFINITY; BONE DEVELOPMENT; BONE METABOLISM; CELL DIFFERENTIATION; DISEASE SEVERITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE;

EID: 0842331943     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(03)00131-3     Document Type: Review

References (36)

1. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luethy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319.
2. Yasuda H., Shima N., Nakagawa N., Mochizuki S., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;1329-1337.
3. 2D3. J Bone Miner Res. 14:1999;1478-1485.
4. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., et al. The murine mutation osteopetrosis in the coding region of the macrophage colony stimulating factor gene. Nature. 345:1990;442-444.
5. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1998;1260-1268.
6. Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cells. 93:1998;165-176.
7. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. J Biol Chem. 272:1997;25190-25194.
8. Kim N., Odgren P.R., Kim D.K., Marks S.C., Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocytes-expressed TRANCE transgene. Proc Natl Acad Sci USA. 97:2000;10905-10910.
9. Hofbauer L.C., Khosla S., Lacey D.L., Dunstan C.R., Boyle W.J., Riggs B.L. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 15:2000;2-12.
10. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp M. 186:1997;2075-2080.
11. Josien R., Wong B.R., Li H.L., Steinman R.M., Choi Y. TRANCE, a TNF family member is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol. 162:1999;2562-2568.
12. Josien R., Wong B.R., Li H.L., Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol. 65:1999;715-724.
13. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPG is a key regulator of osteoclastogenesis, lymphocytes development and lymph-node organogenesis. Nature. 397:1999;315-323.
14. Horwood N.J., Kartsogiannis V., Quinn J.M.W., Romas E., Martin T.J., Gillepsie M.T. Activated T cells support osteoclast formation in vitro. Biochem Biophis Res Commun. 265:1999;144-150.
15. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:1999;604-609.
16. Kotake S., Udagawa N., Hadoka M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes, possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthtritis Rheum. 44:2001;1003-1012.
17. Lacey D.L., Erdmann J.M., Teitelbaum S.L., Tan H.L., Ohara J., Shioi A. Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology. 136:1995;2367-2376.
18. Feldmann M., Brennan F., Paleolog E., Taylor P., Maini R.N. Anti tumor necrosis factor alpha therapy of rheumatoid arthritis: mechanism of action. Eur Cytokine Netw. 8:1997;297-300.
19. Goldring S.R., Gravallese E.M. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 12:2000;195-199.
20. Suda T., Takahashi N., Udagawa N., Jimi E., Gillepsie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endoc Rev. 20:1999;345-357.
21. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., et al. Interleukin-6 and soluble interleukin 6 receptors in the synovial fluids from rheumatoid arthritis patient are responsible for osteoclast-like cell formation. J Bone Miner Res. 11:1996;88-95.
22. Weitzmann M.N., Cenci S., Rifas L., Brown C., Pacifici B. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood. 96:2000;1873-1878.
23. Gravallese E.M., Manning C., Tsay A., Naito A., Pan C., Amento E., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43:2000;250-258.
24. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp M. 191:2000;275-285.
25. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:1996;255-259.
26. Takayanagi H., Oda H., Yamamoto S., Kawaguchi H., Tanaka S., Nishikawa T., et al. A new mechanism of bone destruction in rheumatoid arthritis; synovial fibroblasts induce osteoclastogenesis. Biochem Biophis Res Commun. 240:1997;279-286.
27. Fujikawa Y., Sabokbar A., Neale S., Athanasou N.A. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis. 55:1996;3597-3602.
28. Romas E., Bakharevski O., Hards D.K., Kartsogiannis V., Quinn J.M.W., Ryan P.F.J., et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43:2000;821-826.
29. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromals cells. Proc Natl Acad Sci. 87:1990;7260-7264.
30. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43:2000;259-269.
31. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 159:2001;1689-1699.
32. Bromley M., Woolley D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27:1984;968-975.
33. Itonaga I., Fujikawa Y., Sabokbar A., Murray D.W., Athanasou N.A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol. 192:2000;97-104.
34. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 46:(7):2002;1744-1753.
35. Bekker P.J., Holloway D., Nakanishi A., Arrighi H.M., Leese P.T., Dunstan C.R. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in post menopausal women. J Bone Miner Res. 16:(2):2001;348-360.
36. Lubberts E., Joosten L., Chabeaud M., Van den Bersselaar L., Oppers B., Coenen-de Roo C., et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest. 105:2000;1697-1710.